Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2319]

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

New MM patients with high levels of circulating tumour cells distinguished by...

Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Exceptional response to oral metronomic chemotherapy in a rare case of...

Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

Anti-cancer drug price regulation in India: Financial implications and annual...

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

Anti-cancer drug price regulation in India: Financial implications and annual savings to patients ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )

Disparities in myeloma: Closing the gap

Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Disparities in myeloma: Closing the gap ( Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

Long-term outcomes and complications in cancer patients who have recovered from...

Dr David Pinato - Imperial College London, London, UK

Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

OncoAlert and ecancer - ESMO 2021 preview

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Multidisciplinary management of ovarian germ cell tumours - a single...

Dr Sandip Ganguly - Tata Medical Center, Kolkata, India

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

More from ecancer